News Headlines Article

Stanford spinout takes new angle against Alzheimer’s, MS, other diseases
San Francisco Business Times

A Stanford University spinout, backed by fresh research on how a common protein in the brain is involved in Alzheimer’s disease, is aiming at a new target for drugs to block a range of neurodegenerative diseases. Annexon Inc., started two years ago by Stanford neurobiology professor Dr. Ben Barres and Rinat Neuroscience founder Arnon Rosenthal, already has interest from potential Big Pharma partners.